Capital World Investors Zentalis Pharmaceuticals, Inc. Transaction History

Capital World Investors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $608,790 - $955,500	13,000 Added 1.94%	683,000 $45.5 Million
Q2 2021 Aug 16, 2021	BUY	$37.41 - $62.25 $11.2 Million - $18.7 Million	300,000 Added 81.08%	670,000 $35.6 Million
Q1 2021 May 14, 2021	SELL	$35.69 - $52.72 $17.1 Million - $25.3 Million	-480,000 Reduced 56.47%	370,000 $16.1 Million
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $5.9 Million - $10.8 Million	186,000 Added 28.01%	850,000 $44.1 Million
Q3 2020 Nov 13, 2020	BUY	$27.03 - $47.97 $5.78 Million - $10.3 Million	214,000 Added 47.56%	664,000 $21.7 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $10.4 Million - $24.7 Million	450,000 New	450,000 $21.6 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

Stay updated on Capital World Investors with notifications on news.